BACKGROUND: Given that obsessive compulsive disorder (OCD) is associated with impaired quality of life (QoL) and functioning, it is important examine whether therapeutic recovery from OCD leads to improvements on these important secondary outcomes. Only a few studies have examined how measures of OCD symptom severity relate to QoL and functioning among patients receiving treatment for OCD. METHODS:OCD severity was measured with the Obsessive-Compulsive Inventory-Revised (OCI-R), a self-report scale of OCD, and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), an interview measure of OCD. Participants were 100 adults with a primary diagnosis of OCD on serotonin reuptake inhibitors (SRIs) enrolled in a randomized clinical trial comparing SRI augmentation with either exposure and response prevention (EX/RP) therapy, risperidone, or pill placebo. At baseline, mid-treatment, and post-treatment, patients completed assessments for OCD symptoms and QoL/functioning measures. Multilevel modeling was used to assess changes in QoL/functioning over the course of treatment and to compare such changes across treatment conditions. RESULTS: Improvements in QoL/functioning were significantly greater among those receiving EX/RP compared to those receiving risperidone. Compared to pill placebo, EX/RP performed better on measures of functioning but not QoL. Greater improvement in individual OCI-R scores was associated with greater improvements in QoL/functioning, regardless of condition. In addition, Y-BOCS scores appeared to moderate improvements in QoL over the course of all treatment conditions, such that those with higher Y-BOCS scores showed the greatest improvements in QoL over time. CONCLUSIONS: Improvements in QoL/functioning were associated with reduction in OCD symptom severity. The implications on OCD treatment and clinical research are discussed.
RCT Entities:
BACKGROUND: Given that obsessive compulsive disorder (OCD) is associated with impaired quality of life (QoL) and functioning, it is important examine whether therapeutic recovery from OCD leads to improvements on these important secondary outcomes. Only a few studies have examined how measures of OCD symptom severity relate to QoL and functioning among patients receiving treatment for OCD. METHODS:OCD severity was measured with the Obsessive-Compulsive Inventory-Revised (OCI-R), a self-report scale of OCD, and the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), an interview measure of OCD. Participants were 100 adults with a primary diagnosis of OCD on serotonin reuptake inhibitors (SRIs) enrolled in a randomized clinical trial comparing SRI augmentation with either exposure and response prevention (EX/RP) therapy, risperidone, or pill placebo. At baseline, mid-treatment, and post-treatment, patients completed assessments for OCD symptoms and QoL/functioning measures. Multilevel modeling was used to assess changes in QoL/functioning over the course of treatment and to compare such changes across treatment conditions. RESULTS: Improvements in QoL/functioning were significantly greater among those receiving EX/RP compared to those receiving risperidone. Compared to pill placebo, EX/RP performed better on measures of functioning but not QoL. Greater improvement in individual OCI-R scores was associated with greater improvements in QoL/functioning, regardless of condition. In addition, Y-BOCS scores appeared to moderate improvements in QoL over the course of all treatment conditions, such that those with higher Y-BOCS scores showed the greatest improvements in QoL over time. CONCLUSIONS: Improvements in QoL/functioning were associated with reduction in OCD symptom severity. The implications on OCD treatment and clinical research are discussed.
Authors: Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas Journal: JAMA Psychiatry Date: 2013-11 Impact factor: 21.596
Authors: Brittany B Kugler; Adam B Lewin; Vicky Phares; Gary R Geffken; Tanya K Murphy; Eric A Storch Journal: Psychiatry Res Date: 2012-10-30 Impact factor: 3.222
Authors: W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney Journal: Arch Gen Psychiatry Date: 1989-11
Authors: Samantha G Farris; Carmen P McLean; Page E Van Meter; Helen Blair Simpson; Edna B Foa Journal: J Clin Psychiatry Date: 2013-07 Impact factor: 4.384
Authors: Sanne Jensen; Katja A Hybel; Davíð R M A Højgaard; Judith Becker Nissen; Bernhard Weidle; Tord Ivarsson; Gudmundur Skarphedinsson; Karin Melin; Nor Christian Torp; Anders Helles Carlsen; Erik Lykke Mortensen; Fabian Lenhard; Scott Compton; Per Hove Thomsen Journal: Eur Child Adolesc Psychiatry Date: 2021-04-21 Impact factor: 5.349
Authors: Johanna A M du Mortier; Karin C P Remmerswaal; Neeltje M Batelaan; Henny A D Visser; Jos W R Twisk; Patricia van Oppen; Anton J L M van Balkom Journal: Front Psychiatry Date: 2021-04-12 Impact factor: 4.157
Authors: Nadja Wolf; Patricia van Oppen; Adriaan W Hoogendoorn; Anton J L M van Balkom; Henny A D Visser Journal: Front Psychiatry Date: 2022-03-24 Impact factor: 4.157
Authors: Eduardo Cinosi; David Adam; Ibrahim Aslan; David Baldwin; Kieran Chillingsworth; Arun Enara; Tim Gale; Kabir Garg; Matthew Garner; Robert Gordon; Natalie Hall; Nathan T M Huneke; Sonay Kucukterzi-Ali; Joanne McCarthy; Daniel Meron; Deela Monji-Patel; Roisin Mooney; Trevor Robbins; Megan Smith; Nick Sireau; David Wellsted; Solange Wyatt; Naomi A Fineberg Journal: Pilot Feasibility Stud Date: 2021-12-06